We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aptamer Group Plc | LSE:APTA | London | Ordinary Share | GB00BNRRP542 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -6.45% | 0.725 | 0.70 | 0.75 | 0.775 | 0.725 | 0.775 | 2,765,570 | 15:07:33 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 1.75M | -7.84M | -0.0168 | -0.43 | 3.36M |
From Dec 2023 to Jun 2024
TIDMAPTA
RNS Number : 0395X
Aptamer Group PLC
15 December 2023
15 December 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Results of 2023 Annual General Meeting
Aptamer Group plc (AIM: APTA), the developer of novel Optimer(R) binders to enable innovation in the life sciences industry, today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today at 10:00 GMT at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 20 November and the full poll results will be made available on the Aptamer website later today.
- ENDS -
For further information, please contact:
Hot Features
Premium
Aptamer Group plc
Steve Hull +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Mark Brady / Adam Dawes +44 (0) 20 3368 3550
-----------------------
T urner Pope I nvestments (TPI) Limited
- B roker
J ames Pope / Andrew Thacker +44 (0) 20 36 57 0 050
-----------------------
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer (R) platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.
Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGEELFFXLLEFBE
(END) Dow Jones Newswires
December 15, 2023 10:57 ET (15:57 GMT)
1 Year Aptamer Chart |
1 Month Aptamer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
